IDCT

BIOLOGICAL2 trials

Sponsors

DiscGenics, Inc.

Conditions

Degenerative Disc Disease

Phase 1

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

CompletedNCT03347708

DiscGenics, Inc.Degenerative Disc Disease

Start: 2018-02-26End: 2022-11-10Updated: 2023-01-25

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration

CompletedNCT03955315

DiscGenics, Inc.Degenerative Disc Disease

Start: 2019-05-23End: 2022-11-28Updated: 2025-11-20

Related Papers

Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration—Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial

The International Journal of Spine Surgery2024-06-0113 citations

Identifying and Managing Sources of Variability in Cell Therapy Manufacturing and Clinical Trials

Regenerative Engineering and Translational Medicine2019-09-0532 citations

In vitro and in vivo evaluation of discogenic cells, an investigational cell therapy for disc degeneration.

2019-08-2033 citations